tocainide
Trade name: tonocard
Approved
Nov 9, 1984
Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose-dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide. The recommended initial dosage is 400 mg every 8 hours. The usual adult dosage is between 1200 and 1800 mg/day in a three-dose daily divided regimen. Doses beyond 2400 mg per day have been administered infrequently. Patients who tolerate the t.i.d. the regimen may be tried on a twice-daily regimen with careful monitoring. Tocainide commonly produces minor, transient, nervous system and gastrointestinal adverse reactions, but is otherwise generally well tolerated. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
1980s
- Nov 9, 1984
AstraZeneca — Earliest FDA Approval
- Nov 9, 1984
Astra — NDA Secondary Org
- Nov 9, 1984
AstraZeneca — NDA Secondary Org
- Nov 9, 1984
AstraZeneca — NDA Organization
Indications
Approved for
Mechanism of action
- Sodium channel alpha subunitBLOCKER
Sodium channel alpha subunit blocker
- Sodium channel protein type 1 subunit alpha (SCN1A) ↗
- Sodium channel protein type 5 subunit alpha (SCN5A) ↗
- Sodium channel protein type 4 subunit alpha (SCN4A) ↗
- Sodium channel protein type 7 subunit alpha (SCN7A) ↗
- Sodium channel protein type 2 subunit alpha (SCN2A) ↗
- Sodium channel protein type 9 subunit alpha (SCN9A) ↗
- Sodium channel protein type 3 subunit alpha (SCN3A) ↗
- Sodium channel protein type 11 subunit alpha (SCN11A) ↗
- Sodium channel protein type 8 subunit alpha (SCN8A) ↗
- Sodium channel protein type 10 subunit alpha (SCN10A) ↗
- Sodium channel protein type I alpha subunit
- Sodium channel protein type V alpha subunit
- Sodium channel protein type IV alpha subunit
- Sodium channel protein type VII alpha subunit
- Sodium channel protein type IX alpha subunit
- Sodium channel protein type II alpha subunit
- Sodium channel protein type III alpha subunit
- Sodium channel protein type XI alpha subunit
- Sodium channel protein type VIII alpha subunit
- Sodium channel protein type X alpha subunit
- Sodium channel alpha subunits; brain (Types I, II, III)
Approval history
- approvedPriority reviewNov 9, 1984
Chemistry & pharmacology
SMILES
Cc1cccc(C)c1NC(=O)C(C)N- Mol. weight
- 192.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1762 ↗
- WikipediaTocainide ↗
- NCATS2K7I38CKN5 ↗
- ChEMBLCHEMBL1200773 ↗
Also known as
- 2-amino-2',6'-propionoxylidide
- 2-amino-2',6'-propionoxylidide
- 2-amino-n-(2,6-dimethylphenyl)propanamide
- 2-amino-n-(2,6-dimethylphenyl)propanamide
- 2-amino-n-(2,6-dimethylphenyl)propionamid
- 2-amino-n-(2,6-dimethylphenyl)propionamid
- alanyl-2,6-xylidide
- alanyl-2,6-xylidide
- dl-tocainide
- (rs)-tocainide
- tocainida
- tocainida
- tocainide
- tocainide
- tocainide
- tocainide
- tocainide
- tocainide
- tocainide
- tocainide
- (+/-)-tocainide
- tocainide hcl
- tocainide hcl
- tocainide hcl
- tocainide hydrochloride
- tocainide hydrochloride
- tocainide hydrochloride
- tocainide hydrochloride
- tocainide hydrochloride
- tocainide hydrochloride
- tocainide hydrochloride
- tocainidum
- tocainidum
- tonocard
- tonocard
- tonocard
- w-36095
- w-36095
- xylotocan
- xylotocan
Organizations
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Astra | For profit | NDA2 | Nov 9, 1984 |
| AstraZeneca | For profit | NDA2 | Nov 9, 1984 |
| AstraZeneca | For profit | NDA | Nov 9, 1984 |